The AFFIRMCOPD Aclidinium and Formoterol Findings In Respiratory Medicine COPD brand, founded in 2013 (Spain), from 239 sister brands and 4958 competing brands. The AFFIRMCOPD Aclidinium and Formoterol Findings In Respiratory Medicine COPD brand is owned by ALMIRALL, a company listed in Madrid. The ISIN, the company's International Securities Identification Number, is ES0157097017. The sector of AFFIRMCOPD Aclidinium and Formoterol Findings In Respiratory Medicine COPD is Drug Manufacturers.
Share price and profitability of the share ALMIRALL (AFFIRMCOPD Aclidinium and Formoterol Findings In Respiratory Medicine COPD)
Buy ALMIRALL share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.
Investment simulator :
Portfolio valuation
ALMIRALL
(AFFIRMCOPD Aclidinium and Formoterol Findings In Respiratory Medicine COPD)
over 5 years*
EUR 4.90
Stock market history ALMIRALL (AFFIRMCOPD Aclidinium and Formoterol Findings In Respiratory Medicine COPD)
*non inclusive of dividends, non inclusive of market orders
past performances do not prejudice future performances
past performances do not prejudice future performances
